The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer.
about
PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancerAnti-Cancer Stem-like Cell Compounds in Clinical Development - An Overview and Critical AppraisalCellular prostatic acid phosphatase, a PTEN-functional homologue in prostate epithelia, functions as a prostate-specific tumor suppressorEmerging therapeutic biomarkers in endometrial cancerSignaling pathways in the development of infantile hemangiomaThe mitochondrial permeability transition pore and cancer: molecular mechanisms involved in cell deathRecent development of ATP-competitive small molecule phosphatidylinostitol-3-kinase inhibitors as anticancer agentsICOS Co-Stimulation: Friend or Foe?Cryptotanshinone induces cell cycle arrest and apoptosis through the JAK2/STAT3 and PI3K/Akt/NFκB pathways in cholangiocarcinoma cells.Rapid estrogen signaling negatively regulates PTEN activity through phosphorylation in endometrial cancer cells.A pan-cancer proteomic perspective on The Cancer Genome Atlas.The emerging genomic landscape of endometrial cancer.The impact of microRNA-mediated PI3K/AKT signaling on epithelial-mesenchymal transition and cancer stemness in endometrial cancer.Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention.Analysis of tumor suppressor genes based on gene ontology and the KEGG pathway.Estrogen receptor expression and increased risk of lymphovascular space invasion in high-grade serous ovarian carcinoma.Mechanisms of GOLPH3 associated with the progression of gastric cancer: a preliminary study.Mammalian target of rapamycin complex 1 and cyclooxygenase 2 pathways cooperatively exacerbate endometrial cancer.Molecular profiling of circulating tumor cells links plasticity to the metastatic process in endometrial cancerTaselisib, a selective inhibitor of PIK3CA, is highly effective on PIK3CA-mutated and HER2/neu amplified uterine serous carcinoma in vitro and in vivoTrichomonas vaginalis metalloproteinase induces mTOR cleavage of SiHa cells.Endoplasmic reticulum stress in endometrial cancer.Melatonin combined with endoplasmic reticulum stress induces cell death via the PI3K/Akt/mTOR pathway in B16F10 melanoma cellsRadiation persistently promoted oxidative stress, activated mTOR via PI3K/Akt, and downregulated autophagy pathway in mouse intestineRelation between outcomes and expression of estrogen receptor-α phosphorylated at Ser(167) in endometrioid endometrial cancerAcquisition of resistance to trastuzumab in gastric cancer cells is associated with activation of IL-6/STAT3/Jagged-1/Notch positive feedback loopDifferential Reponses of Hematopoietic Stem and Progenitor Cells to mTOR Inhibition.Would the combination of everolimus with endocrine-therapy help in FGFR2 positive serous endometrial cancer?Molecular staging of gynecological cancer: What is the future?Ailanthone Inhibits Huh7 Cancer Cell Growth via Cell Cycle Arrest and Apoptosis In Vitro and In Vivo.Cryptotanshinone activates AMPK-TSC2 axis leading to inhibition of mTORC1 signaling in cancer cells.MicroRNA-199a-3p suppresses glioma cell proliferation by regulating the AKT/mTOR signaling pathwayStratification of clear cell renal cell carcinoma (ccRCC) genomes by gene-directed copy number alteration (CNA) analysisCisplatin regulates cell autophagy in endometrial cancer cells via the PI3K/AKT/mTOR signalling pathway.TDRG1 functions in testicular seminoma are dependent on the PI3K/Akt/mTOR signaling pathwayA tale of two approaches: complementary mechanisms of cytotoxic and targeted therapy resistance may inform next-generation cancer treatmentsMicroRNA-495 downregulates FOXC1 expression to suppress cell growth and migration in endometrial cancer.Clinical implications of Girdin and PI3K protein expression in breast cancer.PI3K pathway dependencies in endometrioid endometrial cancer cell lines.Five endometrial cancer risk loci identified through genome-wide association analysis.
P2860
Q24185960-FB3E1EF5-03C0-40DC-A6B4-F64ED7B8894DQ26744536-7E16BDFC-BF64-4FB9-BDB4-52543FE8C284Q26863333-119794D0-465C-4A99-96DC-87A48697CB60Q26865904-B5391005-784F-4C45-99C3-B4628F0AAAC4Q26996608-0FEB2A7D-2EE5-46BE-9D71-129180BAF9A3Q27012559-FA390246-DEE2-4D33-B2BE-614F3F2191FFQ28067417-64D7EDF2-E461-4CCF-A5D7-5BA5A992E559Q28072305-842AB292-C52B-4E21-A27F-02EA48B6ABE4Q32174351-66E6C982-4B66-4751-9856-213DEC650B82Q33921596-15E9F4A0-0123-47D6-B217-ADD5829555DBQ33944976-95DE9EDB-1AC9-48D5-B766-F31DEBA0DC05Q34026976-11655308-48F7-48D7-ACD7-628E0279A6E2Q34091442-47387584-0F6A-4CD4-AB98-1E12F5704157Q34103963-024B3080-5370-4E3A-8768-64F8417C6969Q34160138-6942D13C-203C-41DF-A707-931F85ED97C5Q34219967-3EF56CC9-6B8A-4DEE-BBD4-6181D2D9EF4CQ34294000-FDD12BA2-BD27-4807-AC18-853C85815EF8Q34299944-00EDC2C1-1797-4EA7-8642-177E83854665Q34310001-95C26660-AA7D-4D87-ABDE-CBC64F89FC59Q34729807-BD1D4F85-56A3-4335-8592-6CD1C2E4E0F9Q34775160-9D103648-DC52-4FCA-BA05-CD72F83547F2Q34928094-303C498A-FE5A-4765-8AA7-17449B22E13FQ35125118-6BF67758-F7CF-4C18-9984-08174F67A176Q35186424-9E30498B-0C0B-403D-B868-CEDCBDE7D163Q35713164-11A4B73A-5CE0-4589-8E04-DB89ED0C492FQ35741610-266455D4-2111-4705-954E-3D565FF7B691Q35843230-8EB0E58A-F61F-43AB-B3EC-84963CE700E8Q35863058-DC38D670-B068-4AE7-BE29-81ADD3D81B75Q35940829-31711B23-82B2-4420-9271-016CE20EB737Q36242619-9F0434C2-FA7E-4828-9790-1DCA37D9B7C0Q36243282-6A6441BA-E758-4B1B-8F4C-0105048FCEC5Q36278102-586AE367-D2CE-484C-858A-273ADB10FBFDQ36367103-9D104841-A8C6-430B-8535-290DC304DA40Q36375807-110BC061-88AB-4D76-9078-65E2DBCB5639Q36498943-A58F1329-AE3F-4F3E-91D8-88C218C5E68EQ36740744-A4D4815F-4D0B-47E5-8F6A-944927360936Q36827700-88E5916F-2223-4F45-B5A9-8F7FC04C0058Q36918959-FC2E2904-7EC8-463C-B0C6-E86403E3987AQ36980561-4A1FDF06-DCDC-436F-B525-D6FBDBBA9D18Q37002930-5F9A46DE-D3A0-4F28-A37A-3EFBFAF1D9FF
P2860
The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer.
@en
type
label
The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer.
@en
prefLabel
The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer.
@en
P1476
The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer.
@en
P2093
Brian M Slomovitz
Robert L Coleman
P304
P356
10.1158/1078-0432.CCR-12-0662
P407
P577
2012-10-18T00:00:00Z